Since the beginning of this year, a large number of pharmaceutical companies have started a fundraising model
.
According to Wind data, as of July 27, 32 pharmaceutical listed companies have launched additional issuance plans during the year, with a total of 34.
082 billion yuan to be raised; 15 companies have completed the fixed increase plan, and the actual total amount of funds raised is nearly 32 billion yuan
.
Recently, the wave of fundraising in the pharmaceutical industry is still continuing, and there are many cases of large-scale fundraising, and most companies say that they are to accelerate innovation and research and development
.
For example, on October 19, Shandong Baiduoan Medical Device Co.
, Ltd.
disclosed the prospectus (draft declaration) that the number of shares to be publicly issued by the company this time shall not exceed 20.
52 million shares, accounting for no less than 25% of the total share capital after the issuance, subject to the number of
registrations approved by the China Securities Regulatory Commission.
In this IPO of the Science and Technology Innovation Board, Baiduoan intends to raise 760 million yuan for medical catheter industrialization upgrade projects, R&D center construction projects, marketing service network and information construction projects, and supplementary working capital projects
.
On October 18, Hengrun Dasheng submitted an IPO application for the Science and Technology Innovation Board, and the prospectus was officially made public
.
Hengrun Dasheng plans to raise RMB 2,539.
48 million in the IPO of the Science and Technology Innovation Board, of which RMB 1.
337 billion will be used for cell therapy research and development, RMB 600 million will be used for the construction of headquarters and industrialization bases, and RMB 600 million will be used to supplement working capital
.
On October 17, Dongfulong issued an announcement that the China Securities Regulatory Commission approved the company's registration application
for issuing shares to specific targets.
The company intends to raise no more than 3.
2 billion yuan, mainly to increase the production capacity of pharmaceutical equipment and replenish working capital
.
According to the announcement, after deducting the issuance expenses, 530 million yuan will be used for the biopharmaceutical equipment industry trial production center project, accounting for 16.
6%; 990 million yuan was used for the Jiangsu biomedical equipment industrialization base project, accounting for 30.
9%; 1.
25 billion yuan was used for the Hangzhou Life Science Industrialization Base Project, accounting for 39.
1%; A further $430 million will be used to replenish working capital
.
On October 13, the GEM Listing Committee of Shenzhen Stock Exchange held the 73rd listing committee review meeting in 2022, and two companies, Anhui Wanbang Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Wanbang Pharmaceutical") and Jiaxing Kaishi Biotechnology Co.
, Ltd.
(hereinafter referred to as "Kaishi Biotechnology") will be reviewed for IPO on
the Growth Enterprise Market (GEM).
It is reported that the two enterprises intend to raise a total of nearly 1.
2 billion yuan.
Among them, Wanbang Pharma intends to raise 484 million yuan, 404 million yuan for the drug research and development and pharmacokinetic engineering center project, including clinical trial service capacity improvement project, pharmaceutical research center upgrade construction project and innovative drug development platform construction project, 80 million yuan for liquidity charging project
.
Kaishi Biologics intends to raise 700 million yuan, which will be used for in vitro diagnostic product production base projects, in vitro diagnostic instrument research and development projects and supplementary working capital
.
On the whole, most domestic pharmaceutical companies are undoubtedly raising funds to increase the layout of innovative research and development
.
In this regard, the industry believes that this is mainly due
to the fact that the country is vigorously supporting pharmaceutical innovation, but innovative products have the characteristics of high R&D investment and high risk, and require continuous cost investment.
In the future, with the continuous increase of capital, the progress of related new drug development is expected to accelerate, and more and more innovative products will continue to emerge
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
